Clinical Trial Update: The Prednisone-sparing Effect of Anti-IL-5 Antibody (SB-240563) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the prednisone-sparing effect of the anti-IL-5 antibody SB-240563 in asthma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• SB-240563 (anti-IL-5 monoclonal antibody)

Snippet

Sponsor: St. Joseph's Healthcare Hamilton | Conditions: Asthma | Phase 2 | Status: COMPLETED